Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
September 12 2024 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September
2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
12
September 2024 - “Haleon plc: EMTN bond
offering”
|
99.1
Haleon plc: EMTN bond offering
12 September 2024: Haleon plc (the "Company" or “Haleon”)
(LSE/NYSE: HLN) today announces that, on 11 September 2024, its
wholly-owned subsidiary, Haleon UK Capital plc, successfully priced
two notes under its Euro Medium Term Note (“EMTN”)
programme (the “Offering”). The Offering is expected to
close on 18 September 2024, subject to customary closing
conditions.
The Offering consisted of the following notes, issued by Haleon UK
Capital plc and fully and unconditionally guaranteed by the
Company:
●
€750,000,000
of fixed rate notes with a coupon of 2.875% maturing on 18
September 2028; and
●
£300,000,000
of fixed rate notes with a coupon of 4.625% maturing on 18
September 2033 (together, the “Notes”)
The Company expects to use the net proceeds of the Offering for
general corporate purposes including partial repayment of the
$1.75bn bond maturing in March 2025.
Barclays, Bank of America, BNP Paribas and JP Morgan acted as joint
book-running managers on the transaction.
The Notes will be issued under Haleon UK Capital plc’s and
Haleon Netherlands Capital B.V.’s £10,000,000,000 EMTN
programme and admitted to trading on the International Securities
Market of the London Stock Exchange.
The Notes have not been registered under the U.S. Securities Act of
1933 and may not be offered or sold in the United States absent
registration or an applicable exemption from
registration.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes described herein, nor
shall there be any sale of these Notes in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Sonya
Ghobrial
|
+44
7392 784784
|
Zoë
Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44
7985 175048
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email:
investor-relations@haleon.com
|
Email:
corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date: September 12,
2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Nov 2023 to Nov 2024
